Advanced Filters
noise

heart-transplantation Clinical Trials

A listing of heart-transplantation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 58 clinical trials
R Rafael Correa-Rocha, PhD

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children

The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries. After completing the pre-clinical studies, the investigators have initiated a phase I/II clinical trial to test the safety and efficacy of the adoptive transfer of autologous thyTreg to prevent rejection in heart …

- 2 years of age All Phase 1/2
S Sebastian Michel, Dr. med.

Study of Organ Perfusion in Heart Transplantation in Children

The goal of this prospective randomized single blind multicenter phase II study is to compare organ perfusion with Custodiol-N and Custodiol in heart transplantation in children of all ages (birth to <18 years) being listed on the waiting list for heart transplantation. The main question it aims to answer is: …

24 - 17 years of age All Phase 2

Effect of Resistance Training in Patients on the Waiting List for Heart Transplant

The present longitudinal, randomized, and blinded clinical trial aims to: Evaluate the effects of resistance training on the functional capacity, quality of life, and cardiac biomarkers of hospitalized patients with heart failure (HF) on the waiting list for heart transplantation (HTx). Evaluate the associations between Fried's frailty classification and functional …

18 - 70 years of age All Phase N/A
T Tahera Alnaseri

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

18 years of age All Phase N/A
C Ciro M Murad, MD

Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation

The goal of this study is to evaluate if hypertonic saline solution can prevent or attenuate acute kidney injury after heart transplantation in the early postoperative phase.

18 years of age All Phase 2
C Cara Donohue

Respiratory Strength Training in Heart Transplant Recipients

This research study is investigating whether completing breathing exercises before surgery helps heart transplant patients recover after surgery. Previous studies have shown that breathing exercises can improve breathing, cough, and swallow function in patients with other diseases/conditions. The current study will investigate the impact of a preoperative respiratory muscle strength …

18 - 90 years of age All Phase N/A
M Michael Khoury, MD

HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)

Heart transplantation is the long-term treatment for children and adults with advanced heart failure. Post-transplant outcomes have improved over time, such that 50% of pediatric heart transplant recipients (HTR) remain alive with a need for re-transplantation 17-years following the initial transplant. With improved short- and medium-term outcomes, focus has shifted …

10 - 18 years of age All Phase N/A
L Lars Gullestad, MD, PhD

DAPAgliflozin for Renal Protection in Heart Transplant Recipients

Kidney failure is common in heart transplant recipients and is a major cause of morbidity and mortality. Sodium-glucose transporter 2 (SGLT2) inhibitors were developed as antidiabetics but were subsequently shown to reduce the incidence of adverse cardiovascular outcomes and protect renal function in non-diabetics as well as diabetics. However, SGLT2 …

18 years of age All Phase 3
B Bojan Vrtovec, MD, PhD

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation and commonly presents as an asymptomatic viral replication. Viral syndrome or tissue-invasive disease (gastroenteritis, pneumonitis, myocarditis or meningitis) are much …

18 - 70 years of age All Phase 2
D David Majure, MD

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

18 - 99 years of age All Phase 2/3

Simplify language using AI